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ABSTRACT Pseudolymphoma is a benign, reversible, inflammatory, reac-
tive, and polyclonal lymphocyte proliferation, which regresses spontane-
ously or heals after elimination of the causal factor. A female patient, aged 
33, presented with a painful, erythematosus, radiant tumor formation on 
the skin in the temporal region. The patient had enlarged lymph nodes 
on the right side of the neck before the appearance of that tumor forma-
tion. The dermatoscopic finding was nonspecific. After the tumor biopsy 
was performed, the diagnosis of reactive lymphatic proliferation – pseu-
dolymphoma or cutaneous lymphoma of B-cell immunophenotype – was 
established histologically. After we completely excised the skin change, 
the immunohistochemical finding indicated fluoride skin lymphocyte 
hyperplasia of B- and T-lymphocytes. The results of other findings were 
normal (serologic test for Borrelia burgdoferi, ultrasound of the cervical 
and supraclavicular lymph nodes, as well as ultrasound of the abdomen 
and axillary and inguinal regions). However, the etiology of the disease 
remains unknown.  This case report confirms that the correlation between 
clinical presentation, dermatoscopic examination, histologic and immu-
nohistochemical analysis, and the therapy response is crucial for diagno-
sis of pseudolymphoma and patient outcome.
KEY WORDS: pseudolymphoma, histology, immunohistochemical analy-
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INTRODUCTION
Pseudolymphoma is a benign, reversible, inflam-
matory, reactive, and polyclonal lymphocyte prolif-
eration, which regresses spontaneously or heals after 
the elimination of the causal factor (1,2). It refers to 
a heterogeneous group of T- or B-cell lymphoprolif-
erative processes, which clinically and histologically 
simulate skin lymphomas. Therefore it is sometimes 
hard to distinguish between them (3). Although 
there is no generally accepted classification, they are 
mostly classified by lymphocyte type as T-cell, B-cell, 
and combined T- and B-cell pseudolymphomas (4). 
T-cell pseudolymphomas encompass actinic reticu-
loid, lymphomatoid contact dermatitis, and lympho-
cytic infiltrations of skin; B-cell pseudolymphomas 
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encompass cutaneous lymphoid hyperplasia, inflam-
matory pseudotumor of the skin; combined T- and 
B-cell pseudolymphomas encompass lymphomatoid 
medication reactions (4-8). Etiologically, endogenous 
(genetic, immunologic) and exogenous factors (insect 
stings and bites, medication, vaccination, ultrasound, 
traumas, tattoos, acupuncture, infections, etc.) play 
an important role in their development (3). Clinically, 
they mostly appear as solitary or multiple red-purple 
nodules or plaques, which are most often located on 
the face, scalp, and torso (9). B-cell pseudolymphoma 
are also more common than T-cell lymphoma and 
they are more common in female patients (10,11).
Diagnosis is based on medical history, clinical pre-
sentation, histologic presentation, and immunophe-
notypic findings. With regard to T-cell pseudolym-
phomas, the infiltrate can be nodular or band-like, 
while B-cell pseudolymphomas typically present as 
nodular infiltrate (1-8). Generally, mixed inflamma-
tory infiltrate (histiocytes, eosinophils, plasma cells, 
lymphocytes, macrophages, preserved and equally 
spaced out follicular dendritic cells, preserved germi-
nal centers, and the lack of staining for BCL-2) indicate 
pseudolymphoma, although there are exceptions 
from these criteria (3,12,13). For pseudolymphomas 
of known etiology, removing the cause leads to spon-
taneous regression within 6 to 8 weeks. Regarding id-
iopathic cases, the clinical course is usually slow and 
chronic (14). The therapy of cutaneous pseudolym-
phoma includes complete formation excision, cryo-
therapy, local radiotherapy, immunomodulators such 
as tacrolimus, topical or intralesional use of cortico-
steroids, hydroxychloroquine, imiquimod, antibiotic 
treatment for pseudolymphomas caused by Borrelia 
burgdorferi, subcutaneous injection of interferon al-
pha, and photodynamic therapy (14-19). 
However, the study of literary data showed only 
a small number of published articles on this subject. 
Due to a lack of clinical experience resulting from 
work with patients with this disease, we present the 
case of our patient with pseudolymphoma.
CASE REPORT
A female patient, aged 33, was admitted to our 
hospital with a painful, erythematosus, radiant tumor 
formation on the skin in the temporal region with a 
diameter of 0.39 inches, which had appeared 10 days 
before the visit (Figure 1). The patient reported en-
larged lymph nodes on the right side of the neck be-
fore the appearance of that tumor formation. The tu-
mor formation did not regress after topical corticoste-
roid and peroral antibiotic therapy which we initially 
introduced. As this was the solitary lesion on the face, 
differential diagnosis took into account basal cell car-
cinoma, clear cell acanthoma, Spitz nevus, granulo-
ma, and lymphoma. The dermatoscopic examination 
was conducted during the dermatological investiga-
tion and the finding was nonspecific. A tumor forma-
tion biopsy was performed. The diagnosis of reactive 
lymphatic proliferation – pseudolymphoma or cuta-
neous lymphoma of B-cell immunophenotype – was 
established histologically (Figure 2). We then decided 
to completely excise the skin change and to send it to 
immunohistochemical analysis. The finding indicated 
fluoride skin lymphocyte hyperplasia of B- and T-lym-
phocytes (Figure 3, Figure 4). Immunohistochemical 
features revealed diffuse infiltrate of T-lymphocytes 
and nodular and diffuse infiltrate of B-lymphocytes
Furthermore, a serologic test for Borelia burgdor-
feri was performed and the finding was negative. 
Figure 1. Clinical picture of our patient with pseudolym-
phoma.
Figure 2. Histological features: normal epidermis and 
dense lymphoid infiltrate in the dermis (hematoxylin and 
eosin ×20).
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Ultrasound of the cervical and supraclavicular lymph 
nodes showed no deviation, and neither did ultra-
sound of the abdomen, axillary, and inguinal regions. 
However, the etiology remains unknown because the 
patient denied the presence of potential etiological 
factor during the relevant timeframe (insect sting 
or bite, taking medications, injections, contact with 
physio-chemical factors).
A control examination after 3 months showed that 
scar cicatrized in an orderly manner, with no signs of 
recurrence and without appearance of new tumor 
formations.
DISCUSSION
Although pseudolymphomas can manifest as a 
broad spectrum of clinical presentations, timely iden-
tification of pseudolymphoma is of major importance, 
so it is necessary to perform the appropriate tests 
in order to establish a definite diagnosis (11). Even 
though there are some possible classifications of this 
group of diseases mentioned above, none of them 
have yet been clearly accepted. According to recent 
literature data, 4 main groups of cutaneous pseudo-
lymphomas can be distinguished based on clinical 
and/or histologic presentation: nodular pseudolym-
phomas, pseudo-mycosis fungoides, other pseudo-
lymphomas (representing distinct clinical entities), 
and intravascular pseudolymphomas (1). When con-
sidering the diagnosis of the skin pseudolymphoma 
and for differentiation between skin lymphomas, the 
most important is the correlation between the clini-
cal presentation and the pathohistological findings. 
In our case there was a sharply delineated skin tumor 
formation in the temporal right region with a diam-
eter of 0.39 inches, which did not regress after topi-
cal corticosteroids and peroral antibiotic therapy. We 
therefore initially decided to perform a biopsy and 
afterwards tumor excision, which produced the his-
tologic and immunohistochemical findings that were 
crucial for establishing the definite diagnosis (20,21). 
Cutaneous pseudolymphoma affects all age 
groups; the pseudolymphoma caused by B. burgdor-
feri is more common in children and younger persons, 
whereas T-cell pseudolymphoma caused by medica-
tions is more common in adults (22). The pseudolym-
phoma induced by B. burgdorferi is mostly a self-limit-
ing reversible lesion but can be the precursor of B-cell 
lymphoma, and its diagnosis is more common where 
lymphocytic infiltration of the skin was the initial 
suspected diagnosis (23,24). Research also showed 
that B. burgdorferi-associated pseudolymphoma can 
present with misleading histopathologic, immuno-
phenotypic, and molecular features, which indicates 
that integration of all data is necessary for a correct 
diagnosis (23). 
Given the diagnostics, significant progress has 
been made in histological classification, immunohis-
tochemistry, and in molecular analysis of pseudolym-
phoma, which has enabled the establishment of more 
precise diagnosis. However, in some patients it is not 
possible to clearly differentiate between pseudolym-
phoma and lymphoma, which represents a serious 
problem. Furthermore, pseudolymphoma can prog-
ress into cutaneous lymphoma if there is a persistent 
antigenic stimulation, indicating the importance of 
clinicopathological monitoring (3,25). Since clinically 
benign inflammatory lesions sometimes look like a 
malignancy, further monitoring is necessary to dis-
tinguish between a benign/inflammatory/malignant 
lesions. This in turn influences the treatment plan and 
prognosis (26-28). Because of this lack of markers that 
can help predict the pseudolymphoma course and 
Figure 4. Immunohistochemical features: nodular and dif-
fuse infiltrate of B-lymphocytes (immunohistochemistry 
CD20, original magnification ×40).
Figure 3. Immunohistochemical features: diffuse infiltrate 
of T-lymphocytes (immunohistochemistry CD3, original 
magnification ×40).
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lymphoma occurrence, patients should be monitored 
for the rest of their life (29). Furthermore, monitoring 
is especially necessary in idiopathic pseudolympho-
ma cases in order to discover any suspected tumor 
changes on time. Though therapy is mostly directed 
at controlling symptoms or minimizing recurrence 
frequency, none of the available treatment options 
disrupt the natural history of pseudolymphoma or re-
duce the risk of developing an associated lymphoma 
(29). 
CONClUSION 
Pseudolymphoma encompasses a broad spec-
trum of various subtypes of diseases which have com-
pletely different presentations, etiology, and therapy. 
We hope that our pseudolymphoma case report, as 
well as other similar cases, can contribute to resolving 
future clinical dilemmas concerning this diagnosis. 
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